Our goal is to be the leading biopharmaceutical company developing and marketing therapies that restore function and improve the lives of people with neurological disorders.

Acorda’s R&D efforts are designed to:

  • Develop CVT-301 and tozadenant as potential therapies for Parkinson’s disease
  • Advance CVT-427 as a potential acute treatment for migraine
  • Determine if SYN120 is a therapeutic option for people with Parkinson’s disease dementia
  • Advance clinical development of rHIgM22, a remyelinating antibody, as a potential treatment for people with MS
Click on a compound in development for more information.
Therapy THERAPEUTIC AREA Phase 1 Phase 2 Phase 3
CVT-301
Parkinson's Disease
 
 
 
TOZADENANT
Parkinson's Disease
 
 
 
SYN120
Parkinson's Disease
 
 
 
BTT1023 (timolumab)
Primary Sclerosing Cholangitis (PSC)
 
 
 
CVT-427
Migraine
 
 
 
rHlgM22
MS